PsiOxus lands $2.7M for ovarian cancer vaccine trial

PsiOxus Therapeutics nabbed £1.7 million ($2.7 million) from the U.K. government-backed Biomedical Catalyst to start a Phase I/II clinical trial of its cancer vaccine. The Ovarian Cancer Treated with AdenoVirus (OCTAVE) study will mark the second clinical trial of the oncolytic vaccine ColoAd1 for the treatment of platinum-resistant, recurrent ovarian cancer. More than 50 ovarian cancer patients will receive multiple doses of the vaccine and will be assessed for immunological responses as well as tumor response and survival. Release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.